Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-Year results of a pilot study

Transplantation Proceedings

Volumn 43, Issue 4, 2011, Pages 1010-1012

  Spagnoletti, G ^a   Favi, E ^a   Gargiulo, A ^a   Salerno, M P ^a   Citterio, F ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; EVEROLIMUS;

ACUTE GRAFT REJECTION; CLINICAL ARTICLE; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; CALCINEURIN; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; KIDNEY TRANSPLANTATION; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957593888     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.03.018     Document Type: Conference Paper

References (10)

1. Vanrenterghem YF, Claes K, Montagnino G, et al: Risk factors for cardiovascular events after successful renal transplantation. Transplantation 85:209, 2008
2. Takemoto SK, Pinsky BW, Schnitzler MA, et al: A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 12:2704, 2007
3. Kahan BD, Camardo JS: Rapamycin: clinical results and future opportunities. Transplantation 72:1181, 2001
4. Schuler W, Sedrani R, Cottens S, et al: SDZ RAD, a new rapamycin derivative: pharmacologic properties in vitro and in vivo. Transplantation 64:36, 1996
5. Vitko S, Margreiter R, Weimar W, et al: For the RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in the novo renal transplant patients. Am J Transplant 5:2521, 2005
6. Nashan B, Curtis J, Ponticelli C, et al, for the 156 Study Group: Everolimus and reduced exposure cyclosporine in de novo renal transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78:1332, 2004
7. Vitko S, Tedesco H, Eris J, et al: Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4:626, 2004
8. Neumayer HH, Paradis K, Korn A, et al: Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 48:694, 1999
9. Kahan BD, Wong RL, Carter C, et al: A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone- treated renal transplant recipients. Transplantation 68:1100, 1999
10. Tedesco-Silva H Jr, Vitko S, Pascual J, et al: 2306 and 2307 study groups. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 20:27, 2007